| TUSC3 |
|---|
 |
| Identifiers |
|---|
| Aliases | TUSC3, D8S1992, M33, MRT22, MRT7, N33, OST3A, tumor suppressor candidate 3, MagT2, SLC58A2 |
|---|
| External IDs | OMIM: 601385; MGI: 1933134; GeneCards: TUSC3 |
|---|
|
|
| Gene location (Mouse) |
|---|
%3C%2Ftitle%3E%3Cdefs%3E%3CclipPath%20id%3D%22alt-text-clip%22%3E%3Crect%20x%3D%220%22%20y%3D%220%22%20width%3D%22100%25%22%20height%3D%22100%25%22%20%2F%3E%3C%2FclipPath%3E%3C%2Fdefs%3E%3Crect%20width%3D%22100%25%22%20height%3D%22100%25%22%20fill%3D%22transparent%22%2F%3E%3Cg%20clip-path%3D%22url(%23alt-text-clip)%22%3E%3Ctext%20x%3D%2250%25%22%20y%3D%2250%25%22%20text-anchor%3D%22middle%22%20dominant-baseline%3D%22middle%22%20fill%3D%22%2354595d%22%20font-size%3D%2216%22%20font-family%3D%22sans-serif%22%3EChromosome%208%20(mouse)%3C%2Ftext%3E%3C%2Fg%3E%3C%2Fsvg%3E) | | Chr. | Chromosome 8 (mouse) |
|---|
| | Band | 8|8 A4 | Start | 39,472,999 bp |
|---|
| End | 39,619,367 bp |
|---|
|
|
|
|
| Wikidata |
|
Tumor suppressor candidate 3 (TUSC3) is a protein that in humans is encoded by the TUSC3 gene on chromosome 8p22.
Structurally, TUSC3 is an integral membrane protein localized to the endoplasmic reticulum (ER) that contains an N-terminal thioredoxin-like domain.
Functionally, TUSC3 exhibits a dual biochemical role. It acts as an accessory subunit of the oligosaccharyltransferase (OST) complex, facilitating N-linked glycosylation of nascent proteins, although no glycosylation abnormalities have been demonstrated in TUSC3-deficient cells.
In addition, 2025 research has established that TUSC3 functions as a key regulator of ER magnesium homeostasis, assembling into a functional complex with the ERMA (TMEM94) magnesium transporter, where it is required for efficient magnesium uptake into the ER lumen. Loss-of-function variants in TUSC3 lead to ER magnesium depletion, which initiates a cellular stress response now understood to be the primary driver of TUSC3-related intellectual disability.
TUSC3 has been studied as a candidate tumor suppressor gene in human cancers. As of 2026, cancer risk has not been reported in individuals with germline biallelic TUSC3 variants.